Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. Verification of the PDE1A antibody.
  • Fig. S2. Changes in LV echocardiographic parameters in CryABR120G tg mice at 4 months of age are consistent with HFpEF.
  • Fig. S3. Representative images of M mode echocardiograms taken from sex- and age-matched NTG and CryABR120G tg mice at the completion of 4 weeks of treatment with the PDE1 inhibitor IC86430 (TG-LSN) or vehicle (TG-Vehicle).
  • Fig. S4. Hemodynamic analysis from sex- and age-matched NTG and CryABR120G tg mice at the end of 4 weeks of treatment with the PDE1 inhibitor IC86430 (TG-IC) or vehicle (TG-Vehicle).
  • Fig. S5. Assessments of aortic pressure at the end of 4 weeks of treatment with the PDE1 inhibitor IC86430 (TG-IC) or vehicle (TG-Vehicle).
  • Fig. S6. Western blot analysis for CryAB levels in the SS fraction of NTG and R120G mouse hearts.
  • Table S1. Echocardiographic measurements at 4 months of age immediately before IC86430 treatment.
  • Table S2. Echocardiographic measurements at the end of 4 weeks of treatment.

Download PDF

Files in this Data Supplement: